J&J Lupus Data, Pfizer ASCO Wins Lift Healthcare

Johnson & Johnson ($JNJ) announced that nipocalimab met the primary endpoint of decreasing disease activity at 24 weeks as measured by SLE Responder Index 4 and demonstrated sustained reduction in disease activity through 52 weeks in the Phase 2 JASMINE study in adults with moderate-to-severe systemic lupus erythematosus. The company also presented new biomarker exploratory analyses from the Phase 2 DAHLIAS study evaluating nipocalimab in adults with moderate-to-severe Sjögren's disease, showing that participants with elevated autoantibody and immunoglobulin G levels showed greater clinical response rates. Pfizer ($PFE) reported breakthrough Phase 3 results for its BRAFTOVI combination in first-line metastatic colorectal cancer and TALZENNA combination in metastatic hormone-sensitive prostate cancer at ASCO 2026. The BREAKWATER trial of BRAFTOVI with cetuximab and FOLFIRI in BRAF V600E mutated metastatic colorectal cancer showed strong efficacy signals in progression-free and overall survival, while the TALAPRO-3 study of TALZENNA with XTANDI in hormone-sensitive prostate cancer also demonstrated positive outcomes.

Agilent Technologies ($A) received FDA approval for the expanded use of PD-L1 IHC 22C3 pharmDx on the Dako Omnis platform to aid in identifying patients with esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer, and gastric or gastroesophageal junction adenocarcinoma who may be eligible for treatment. Bristol Myers Squibb ($BMY) secured EU approval for Opdivo plus AVD in newly diagnosed advanced classical Hodgkin lymphoma and advanced Camzyos label expansion review. Gilead Sciences ($GILD) secured accelerated U.S. approval for Hepcludex in chronic hepatitis delta and received a positive EU opinion to broaden Trodelvy's use in metastatic triple-negative breast cancer in late May 2026. Dexcom ($DXCM) disclosed FDA-enforced Class II voluntary recalls of its G7 and ONE/ONE+ iOS and watchOS apps worldwide in May 2026 due to a software defect that can delay or replay glucose readings and alerts.

The global CRISPR-based gene editing market was valued at approximately USD 3.65 Billion in 2024 and is expected to reach USD 4.10 Billion in 2025, ultimately expanding to USD 12.6 Billion by 2034 at a CAGR of 13.01% between 2025 and 2034, according to a market research study. Eli Lilly ($LLY) is advancing its gene editing pipeline, signaling the pharmaceutical industry's growing interest in CRISPR technology as a potential growth driver. The drug industry has been working on methods to shuttle drugs through the blood-brain barrier for Alzheimer's treatments, with results expected to become apparent this year.

Moderna ($MRNA) expanded its collaboration with CEPI to accelerate development of an mRNA vaccine targeting Bundibugyo ebolavirus, focusing on responding to an ongoing Ebola outbreak in Central Africa where no approved vaccines currently exist for this strain. CEPI funding is intended to support rapid research and early stage development using Moderna's mRNA platform for epidemic preparedness. The company also launched Moderna Direct with eCommerce Powered by FFF Enterprises to deliver an enhanced ordering experience for customers, built on BioSupply and FFF Enterprises' platform.

Novo Nordisk has begun its global rollout with a UAE launch, with additional launches planned later this year. Gilead Sciences ($GILD) reported new Phase 3 post hoc data in late May 2026 showing that Livdelzi produced high, durable reductions in key liver markers for people with primary biliary cholangitis, consolidating its position in liver disease and oncology. The United States healthcare market has shown strong performance, rising 1.6% over the last week and climbing 28% in the past year, with earnings forecasted to grow by 17% annually.